clonoSEQ Assay Approved in New York to Measure MRD in Myeloma, Other Blood Cancers
The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow, blood, or tissue sample —…
clonoSEQ Assay Now Covered by Medicare for Multiple Myeloma and Acute Lymphoblastic Leukemia
The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow — will now be covered…
FDA Clears ClonoSEQ Assay for Measuring Minimal Residual Disease in Myeloma, Leukemia
The U.S. Food and Drug Administration (FDA) has approved Adaptive Biotechnologies’ clonoSEQ Assay to detect and monitor minimal residual disease (MRD) — the…
Patient Power, Winship Cancer Institute Partnered for Myeloma Town Hall Meeting
In an effort to inform multiple myeloma patients and their loved ones about cutting-edge research and what it means for them, Patient Power…
Companies Collaborating to Use ClonoSEQ Assay in Multiple Myeloma Trials Testing Isatuximab
Adaptive Biotechnologies is collaborating with Sanofi to use its clonoSEQ Assay for measuring minimal residual disease in multiple myeloma patients receiving isatuximab, a treatment…
Adaptive Biotechnologies, Amgen Partner in Phase 3 CANDOR Trial for Multiple Myeloma
Adaptive Biotechnologies has partnered with Amgen to use Adaptive’s NGS-based clonoSEQ Assay in a Phase 3 clinical trial led by Amgen to…
